Silence Therapeutics plc (NASDAQ:SLN) Receives $33.83 Average Price Target from Analysts

Silence Therapeutics plc (NASDAQ:SLN) has been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $33.83.

A number of brokerages have commented on SLN. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. The Goldman Sachs Group decreased their target price on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research note on Friday, May 9th. Morgan Stanley decreased their target price on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Chardan Capital decreased their target price on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, BMO Capital Markets decreased their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently made changes to their positions in SLN. Nantahala Capital Management LLC raised its holdings in Silence Therapeutics by 424.8% during the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after purchasing an additional 849,676 shares in the last quarter. Redmile Group LLC raised its holdings in Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after purchasing an additional 500,000 shares in the last quarter. Bank of America Corp DE raised its holdings in Silence Therapeutics by 48,165.6% during the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock worth $3,434,000 after purchasing an additional 498,032 shares in the last quarter. Marshall Wace LLP raised its holdings in Silence Therapeutics by 190.3% during the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock worth $3,364,000 after purchasing an additional 320,472 shares in the last quarter. Finally, Cantor Fitzgerald L. P. raised its holdings in Silence Therapeutics by 61.5% during the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company’s stock worth $3,713,000 after purchasing an additional 205,534 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $5.24 on Friday. The company has a market capitalization of $156.83 million, a price-to-earnings ratio of -3.34 and a beta of 1.41. Silence Therapeutics has a one year low of $1.97 and a one year high of $22.47. The stock has a 50-day simple moving average of $4.00 and a 200 day simple moving average of $4.98.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, equities research analysts forecast that Silence Therapeutics will post -1.77 EPS for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.